These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1949939)

  • 21. Role of immunomodulator therapy in sepsis.
    Caplan ES
    Am J Surg; 1993 Feb; 165(2A Suppl):20S-25S. PubMed ID: 8438996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI.
    Rogy MA; Moldawer LL; Oldenburg HS; Thompson WA; Montegut WJ; Stackpole SA; Kumar A; Palladino MA; Marra MN; Lowry SF
    Ann Surg; 1994 Jul; 220(1):77-85. PubMed ID: 8024362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group.
    Derkx B; Wittes J; McCloskey R
    Clin Infect Dis; 1999 Apr; 28(4):770-7. PubMed ID: 10825037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiendotoxin antibodies.
    Siegel JP
    Ann Intern Med; 1995 Feb; 122(4):315-6. PubMed ID: 7825773
    [No Abstract]   [Full Text] [Related]  

  • 25. Single-dose pharmacokinetics and safety of HA-1A, a human IgM anti-lipid-A monoclonal antibody, in pediatric patients with sepsis syndrome.
    Romano MJ; Kearns GL; Kaplan SL; Jacobs RF; Killian A; Bradley JS; Moss MM; Van Dyke R; Rodriguez W; Straube RC
    J Pediatr; 1993 Jun; 122(6):974-81. PubMed ID: 8501580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival in selected patients with gram-negative sepsis after adjunctive therapy with HA-1A.
    van Dissel JT; van Furth R; Compier BA; Feuth HD; Frolich M
    Lancet; 1993 Apr; 341(8850):959-60. PubMed ID: 8096292
    [No Abstract]   [Full Text] [Related]  

  • 27. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.
    Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal anti-endotoxin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Baumgartner JD
    Eur J Clin Microbiol Infect Dis; 1990 Oct; 9(10):711-6. PubMed ID: 2261915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Passive immunotherapy of gram-negative bacteremia, sepsis and septic shock.
    Spapen HD; Diltoer M; Huyghens LP
    Acta Clin Belg; 1993; 48(1):20-9. PubMed ID: 7684546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis.
    Quintiliani R; Cooper B; Maderazo E; Nightingale C
    Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome.
    Fisher CJ; Zimmerman J; Khazaeli MB; Albertson TE; Dellinger RP; Panacek EA; Foulke GE; Dating C; Smith CR; LoBuglio AF
    Crit Care Med; 1990 Dec; 18(12):1311-5. PubMed ID: 2245602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5.
    Marra MN; Thornton MB; Snable JL; Wilde CG; Scott RW
    Crit Care Med; 1994 Apr; 22(4):559-65. PubMed ID: 8143464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo].
    Wortel CH; von der Möhlen MA; van Deventer SJ; Schipper HG; Lorijn RH; ten Cate JW
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):350-4. PubMed ID: 8437633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody to endotoxin in the treatment of gram-negative sepsis.
    Schentag JJ
    JAMA; 1992 May; 267(17):2326-7. PubMed ID: 1564766
    [No Abstract]   [Full Text] [Related]  

  • 35. Antibody to endotoxin in the treatment of gram-negative sepsis.
    Spalter J
    JAMA; 1992 May; 267(17):2325; author reply 2326. PubMed ID: 1564764
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy of endotoxemia and septicemia.
    Baumgartner JD; Glauser MP
    Immunobiology; 1993 Apr; 187(3-5):464-77. PubMed ID: 8330909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide.
    Bogard WC; Siegel SA; Leone AO; Damiano E; Shealy DJ; Ely TM; Frederick B; Mascelli MA; Siegel RC; Machielse B
    J Immunol; 1993 May; 150(10):4438-49. PubMed ID: 7683319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies to endotoxin in the management of sepsis.
    Fang KC
    West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
    Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM
    Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.